ALFA Finder
The call has ended.
Key takeaways
Q2 FY27 group revenue grew 2% YoY, with about 5% (~$20M) deferred to Q3 by a one-off shipment timing issue. Management guides a stronger H2 but gave no hard H2 numbers.
| Revenue growth | Group revenue +2% YoY Q2; biopharma +5%; ~5% revenue deferred to Q3. |
|---|---|
| Margins | Generics EBITDA margin 8% vs 1% YoY; Q2 group hit by deferral. |
| Order book | Brazil PDP $400M 10-year contract; no order book figures. |
| Demand visibility | Glargine demand exceeds supply; order visibility high for aflibercept, pertuzumab. |
| Management confidence | Confident; 'very confident' on H2, but leans on deferred-revenue catch-up. |
Growth
Group revenue +2% YoY, biopharma +5%; H1 +6% to ₹8,725 Cr. Q2 understated by ~5% deferral; EBITDA ₹865 Cr.
Outlook
H2 guided stronger than H1 with 'strong double-digit' USD growth; Brazil supplies begin Q4FY27, full run-rate FY28.
Risks
Deferral recovery depends on Q3 execution; Syngene in transition with lower biologics client demand; Part B price erosion.
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Biocon Q2 FY27 Results: Net Profit ₹56.7 Cr, Down 57.3% YoY
Biocon Ltd reported revenue from operations of ₹4,389 Cr (+2.2% YoY) and net profit of ₹56.7 Cr (-57.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.7 Cr · -57.3% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Launching 5 new biosimilars in FY27. Net Debt/EBITDA target of <2x; no major capex for FY27-28.
Growth they described
FY26 revenue grew 11% YoY; Biosimilars rose 16% to ₹10,431 Cr. Reported Net Profit fell to ₹386 Cr.
Call details
| Company | Biocon Limited |
|---|---|
| NSE symbol | BIOCON |
| ISIN | INE376G01013 |
| Call | Q2 FY27 earnings call |
| Date | Wednesday, 4 November 2026 |
| Time | 4:00 PM IST |
Biocon Limited: key numbers
- Share price
- ₹371.15
- Market cap
- ₹60,486 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 133.8×Sector 43.8×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Wed, 4 Nov
Today's concalls →
